Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alison Bateman-House

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|October 15, 2025
Addressing US Demand for Psychedelic Medicines in the Face of Scientific UncertaintyHolly Fernandez Lynch, Xinping Hu, Alison Bateman-House
Academic Medicine : Journal of the Association of American Medical Colleges|October 11, 2019
Academic Advocacy: Opportunities to Influence Health and Science Policy Under U.S. Lobbying LawHolly Fernandez Lynch, Alison Bateman-House, Suzanne M Rivera
The American Journal of Bioethics : AJOB|October 19, 2021
Helpful Lessons and Cautionary Tales: How Should COVID-19 Drug Development and Access Inform Approaches to Non-Pandemic Diseases?Holly Fernandez Lynch, Arthur Caplan, Patricia Furlong, et al.
Annals of Internal Medicine|September 29, 2015
Right-to-try laws: hope, hype, and unintended consequencesAlison Bateman-House, Laura Kimberly, Barbara Redman, et al.
Pharmaceutical Medicine|December 17, 2022
Somatic Gene Therapy Research in Pediatric Populations: Ethical Issues and Guidance for Operationalizing Early Phase TrialsAlison Bateman-House, Lesha D Shah, Rafael Escandon, et al.
JAMA Network Open|February 17, 2023
Navigating the Expanded Access Pathway to Investigational Drugs as an Academic OncologistHolly Fernandez Lynch, Tasnim Salam, Patrick Gould, et al.
JAMA Network Open|November 1, 2022
Perspectives of Academic Oncologists About Offering Expanded Access to Investigational DrugsPatrick Gould, Tasnim Salam, Laura Kimberly, et al.
The American Journal of Bioethics : AJOB|May 29, 2019
Preapproval Nontrial Access and Off-Label Use: Do They Meet Criteria for Dual-Deviation Review?Carolyn Riley Chapman, Kelly McBride Folkers, Andrew McFadyen, et al.
Therapeutic Innovation & Regulatory Science|September 19, 2018
Pre-approval Access Terminology: A Cause for Confusion and a Danger to PatientsLaura L Kimberly, Marc M Beuttler, Michael Shen, et al.
Medicine Access @ Point of Care|October 7, 2022
A survey of pediatric hematologists/oncologists' perspectives on single patient Expanded Access and Right to TryCarolyn Riley Chapman, Hayley M Belli, Danielle Leach, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|October 15, 2025
Addressing US Demand for Psychedelic Medicines in the Face of Scientific UncertaintyHolly Fernandez Lynch, Xinping Hu, Alison Bateman-House
Academic Medicine : Journal of the Association of American Medical Colleges|October 11, 2019
Academic Advocacy: Opportunities to Influence Health and Science Policy Under U.S. Lobbying LawHolly Fernandez Lynch, Alison Bateman-House, Suzanne M Rivera
The American Journal of Bioethics : AJOB|October 19, 2021
Helpful Lessons and Cautionary Tales: How Should COVID-19 Drug Development and Access Inform Approaches to Non-Pandemic Diseases?Holly Fernandez Lynch, Arthur Caplan, Patricia Furlong, et al.
Annals of Internal Medicine|September 29, 2015
Right-to-try laws: hope, hype, and unintended consequencesAlison Bateman-House, Laura Kimberly, Barbara Redman, et al.
Pharmaceutical Medicine|December 17, 2022
Somatic Gene Therapy Research in Pediatric Populations: Ethical Issues and Guidance for Operationalizing Early Phase TrialsAlison Bateman-House, Lesha D Shah, Rafael Escandon, et al.
JAMA Network Open|February 17, 2023
Navigating the Expanded Access Pathway to Investigational Drugs as an Academic OncologistHolly Fernandez Lynch, Tasnim Salam, Patrick Gould, et al.
JAMA Network Open|November 1, 2022
Perspectives of Academic Oncologists About Offering Expanded Access to Investigational DrugsPatrick Gould, Tasnim Salam, Laura Kimberly, et al.
The American Journal of Bioethics : AJOB|May 29, 2019
Preapproval Nontrial Access and Off-Label Use: Do They Meet Criteria for Dual-Deviation Review?Carolyn Riley Chapman, Kelly McBride Folkers, Andrew McFadyen, et al.
Therapeutic Innovation & Regulatory Science|September 19, 2018
Pre-approval Access Terminology: A Cause for Confusion and a Danger to PatientsLaura L Kimberly, Marc M Beuttler, Michael Shen, et al.
Medicine Access @ Point of Care|October 7, 2022
A survey of pediatric hematologists/oncologists' perspectives on single patient Expanded Access and Right to TryCarolyn Riley Chapman, Hayley M Belli, Danielle Leach, et al.
Pageof 5